Thematic research platforms (Vision, Oncology, Central Nervous system, Infectious diseases)

Neurology specific tools and facilities

Cellular and molecular research (Optogenetics, Cell imaging, molecular genetics, lentiviral transgenesis, Robotized cell culture system, iPS platform)

Functional exploration (Behaviour exploration, EEG / 11,7T MRI)

Neuroimagery platform (3T research MRI, MEG, EEG, TMS)

  • The Electrophysiology core facility is part of the Cell Culture Core facility and provides a choice of full services for projects using electrophysiological approaches.
  • The gait, equilibrium, posture, movement, TMS & NBS platform works on two axis, the use of non-invasive cerebral stimulation in neurological and psychiatric diseases, and the study of gait and equilibrium in patients with neurological diseases.
  • Gliotex project aims to accelerating the evaluation of new innovative therapeutic compounds in in vitro and in vivo well characterized preclinical models of glioblastoma.
  • iPS platform produce induced-pluripotent stem (iPS) in order to model in a culture dish degenerative disorders of the brain and the spinal cord.
  • The MEG & EEG platform develops two non-invasive methods, which allow visualizing brain activity on a millisecond time scale for research and clinical purpose.
  • The MRI platform works on three different axis, clinical research with a focus on the pathophysiology of neurological diseases, cognitive neuroscience, and image processing.
  • The small animal MRI platform is part of the Center for Neuroimaging Research (CENIR). This platform is dedicated to imaging experimental models of neurological diseases.
  • The virtual reality platform develops and adapts new virtual reality paradigms for behavioral and cognitive neurosciences and therapeutic research for psychiatric diseases.

Infectious and parasitic specific research facilities

CRBIP: The Biological Resource Center of Institut Pasteur

The CRBIP preserves collections of biological strains and the information linked to them. A certain number of controls are performed to assure the similarity of the strains with their characteristics (patent rights) coming from the depositor. This information is gathered in a computer database (ARPAS software) and a catalogue which makes easy access of these biological resources for customers and researchers, and maintains an availability and durability for a future use.

CRBIP delivers its biological strains in France and abroad according to the regulations and laws in force on health and environment, so preserving a strong visibility.
Besides, CRBIP is permanently growing by inserting new collections and by diversifying the existing ones. Therefore, more and more new strains are becoming available.
Collection of Institut Pasteur (CIP), Fungi Culture Collection (UMIP), Pasteur culture Collection of Cyanobacteria (PCC) and Biobank ICARe «Access to Biological Resources» are parts of the CRBIP.
In 2007, the CIP gathered 9500 bacteria strains and new ones are regularly being integrated, at a rate of 300 to 400 a year.
Moreover, CRBIP participates in the opening of an international network of BRCs.
The collections meet the requirements of the international standard ISO 9001.

Imagopole

The Imagopole is a center dedicated to imaging research in the life sciences. Its four technological platforms (Dynamic Imaging, Ultrastructural Microscopy, Flow Cytometry, and the Center for Human Immunology) were officially accredited by IBiSA in 2009, and, together, have around forty imaging systems that are used 40,000 hours a year by around 500 scientists. The Imagopole is used by several hundred researchers at the Institut Pasteur and throughout France and, building on its international reputation, the center has fostered many close collaborations with research groups outside of France. The Imagopole has recently renewed its ISO 9001:2008 certification, which guarantees commitment to constantly improving quality of service and relations with its users.

The Imagopole also works to develop and apply methods for host-pathogen interaction research at the molecular and cellular levels, as well as for tissues and entire organisms. The portfolio includes in situ analysis of sub-cellular dynamics, such as spatio-temporal parameters based on the observation of fluorescent and/or bioluminescent tracers. The development and management of mathematical, bioinformatic, and statistical approaches facilitate data analysis.

Proteopole

The Proteopole (IBiSA-accredited since 2008) focuses its combination of high-level technological and methodological expertise on the analysis of macromolecules, and more specifically, proteins. Their wide range of work includes:

  • protein production in microorganisms (prokaryotes/ eukaryotes), insect and mammal cells;
  • production of monoclonal recombinant antibodies;
  • protein identification and analysis using mass spectrometry and analytical chemistry;
  • biophysical characterization at the molecular level: spectroscopy and hydrodynamics, surface plasmon resonance, and microcalorimetry;
  • structural characterization at the atomic level, particularly using X-ray crystallography.

By leveraging synergies between different methods of analysis, the Proteopole can provide research teams with answers to vital questions as well as pinpoint new areas for analysis. Its 32-member staff working in the four platforms provides a wide range of services.

CEPIA

The activities and organization of the Center for the Production and Infection of Anopheles (CEPIA) are geared towards researching interactions of the Plasmodium parasite (malaria agent) with its mammalian and insect hosts (mice or cell lines and mosquitoes of the Anopheles genus, respectively). The platform mass-produces two species of Anopheles: An. gambiae, the African vector, and An. stephensi, the Asian vector. It is the only French structure specialized in the experimental infection of mosquitoes with the human parasite P. falciparum. A range of equipment and facilities is provided for studying interactions between Anopheles and Plasmodium (cell biology and functional genomics) and for the production of sporozoites, the infectious stages of the parasite for the mammal host.

Lymphoma specific research facilities

CeVi_collection

A better understanding of the disease biology is needed to develop new treatments for lymphoma patients. CALYM teams benefit from a viable cell collection, the CeVi Collection, to support their research activities. CeVi collection is a unique human viable cell collection perfectly annotated (histopathology, phenotype, clinical features), issued mainly from lymph nodes, peripheral blood, bone marrow or any other site of a potential tumor proliferation, from lymphomas and reactive lymphoid tissues. Goals are the :

  • development of in vivo and in vitro models
  • study of the role of the microenvironment
  • study of molecular heterogeneity
  • identification of peripheral blood and tissue biomarkers specific to each lymphoma subtype.

Associated biospecimen ressources for a same patient will also potentially include:

  • viable cells from any other site of a potential tumor proliferation
  • blood and marrow plasma
  • frozen cell pellets (DNA/RNA extraction)
  • FFPE tissue blocks

Lymphoma imaging

The imaging platform dedicated to lymphoma organizes centralized proofreading of imaging (PET, CT) made in the clinical centers using the internet solution Imagys. It allows a quick review of imaging examinations for treatment decision making in protocols.
NanoSIMS 50 ion probe: unique microprobe for ultra fine feature analysis in cell biology (only twenty such instruments existed in the world in 2010).

Cancer Study facilities

  • The Nikon Imaging Center @Institut Curie - CNRS, which has celebrated its fifth anniversary in 2012. This scientific imaging platform is unlike any other in France and makes it possible to observe cells to one billionth of a meter or reconstruct their appearance in volume.
  • The high-throughput BioPhenics Platform uses image analysis algorithms to quantify the impact on cells of altered expression of specific genes. This technology enables identification of target molecules for pharmacological research and candidate drugs likely to be more effective against cancer and less toxic to the patient.
  • The high-throughput sequencing platform, funded by the national Equipex program (équipements d’excellence), is a bridge between basic research and medical applications, particularly in development of personalized treatment.
  • Chemolibrary. The Institut Curie-CNRS compound library or chemolibrary contains over 8,000 compounds. The screening of this collection against a wide panel of therapeutically interesting targets has already led to the discovery of a significant number of structurally novel ‘hits’S

Vision dedicated platforms

Several shared facilities set up at the Institut de la Vision to address the Visual Impairment Programs:

  • Our high-throughput and high content screening platform with original cellular models for studying potential therapeutic compounds against eye diseases
  • A Neuro-psycho-physics unit where visual performance and the impact of visual impairment (including tests with a low vision virtual simulator) are assessed
  • The phenotyping platform for sensory systems top-level phenotyping platform for sensory systems on non-human primates for characterizing disease models and assessing new therapeutic treatments
  • A testing apartment ‘Homelab’ where daily life situations and solutions are tested in real life
  • The PANAMMES program with the City of Paris, enabling the testing of urban tools and arrays for the visually and auditory impaired
  • The Streetlab facility conceived and whose construction is currently being overseen by a Robotics lab and researchers from the Institute (Dr. R. Benosman). This newly funded and founded entity is a subsidiary of the Institute, University and several partners dealing with visual impairment, supported by public (state, city and regional) and private funding. The Streetlab facility will simulate (in both real and virtual paradigms) different types of environments that challenge the visually impaired daily, in order to conceive and validate new solutions.
  • Romeo Project. The objective of the Romeo project, managed by Aldebaran, is to develop a robot which will serve as personal assistant to ageing and partially-sighted people.

GLOBAL CARE is an outstanding consortium of 5 French expertises :